MyFinsight
Home
Blog
About
Contact
Download
Download image
Sales and maturities
of marketable...
$104,284K
Proceeds from issuance of
common stock upon...
$871K
Proceeds from issuance of
common stock under...
$132K
Net cash provided by
investing activities
$29,738K
Net cash provided by
(used in) financing...
$257K
Canceled cashflow
$74,546K
Canceled cashflow
$746K
Net (decrease)
increase in cash and cash...
-$16,396K
Canceled cashflow
$29,995K
Stock-based compensation
expense
$3,729K
Prepaid expenses and
other current assets
-$1,970K
Depreciation and
amortization expense
$104K
Other assets
-$88K
Purchases of marketable
securities
$74,546K
Issuance of restricted
stock units
$746K
Net cash used in
operating activities
-$46,391K
Canceled cashflow
$5,891K
Other segment items
-$2,568K
Net loss
-$45,440K
Accounts payable
-$3,499K
Canceled cashflow
$2,568K
Accrued expenses and
other liabilities
-$2,709K
Accretion of premium and
discounts on marketable...
$581K
Operating lease
liabilities
-$53K
Total research and
development expense
$39,210K
Total general and
administrative
$5,069K
Stock based
compensation
$3,729K
Back
Back
Cash Flow
Atea Pharmaceuticals, Inc. (AVIR)
Atea Pharmaceuticals, Inc. (AVIR)
source: myfinsight.com